GLP1R and pancreatitis: A cohort study revealed an increased risk of pancreatitis, and 36% of patients who used GLP-1 RAs or DPP- 4 inhibitors had elevated serum amylase or lipase (or both) levels compared with 18% of patients not taking these agents (31).